Literature DB >> 2853056

4-quinolones inhibit biotransformation of caffeine.

S Harder1, A H Staib, C Beer, A Papenburg, W Stille, P M Shah.   

Abstract

The pharmacokinetics of caffeine, including formation of its major metabolite paraxanthine in plasma, has been investigated in 12 healthy males (age 20-40 years) alone and during co-administration of the 4-quinolones ofloxacin, norfloxacin, pipemidic acid, ciprofloxacin, and enoxacin; ciprofloxacin and enoxacin were given in 3 different dose levels. The naphthyridine derivative enoxacin and the pyrido-pyrimidine derivative pipemidic acid had caused marked inhibition of caffeine and paraxanthine metabolism, whereas the genuine quinolone derivatives norfloxacin and ciprofloxacin had little effect, and the pyrido-benzoxacine derivative ofloxacin had no detectable effect. The different molecular and spatial structures of the compounds appear to be responsible for the differences in inhibitory potency.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2853056     DOI: 10.1007/bf00637602

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  New synthetic quinolone antibacterial agents and serum concentration of theophylline.

Authors:  Y Niki; R Soejima; H Kawane; M Sumi; S Umeki
Journal:  Chest       Date:  1987-10       Impact factor: 9.410

2.  [Gyrase inhibitors can delay caffeine elimination].

Authors:  A H Staib; S Harder; S Mieke; C Beer; W Stille; P M Shah; K Frech
Journal:  Dtsch Med Wochenschr       Date:  1986-09-26       Impact factor: 0.628

3.  Mexiletine and caffeine elimination.

Authors:  R Joeres; E Richter
Journal:  N Engl J Med       Date:  1987-07-09       Impact factor: 91.245

4.  Quinolones and raised plasma concentrations of theophylline.

Authors:  F P Maesen; J P Teengs; C Baur; B I Davies
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

5.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

6.  Danger of interaction between ciprofloxacin and theophylline.

Authors:  J L Bem; R D Mann
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-16

Review 7.  The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics.

Authors:  D E Nix; J J Schentag
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

8.  Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes.

Authors:  M E Campbell; D M Grant; T Inaba; W Kalow
Journal:  Drug Metab Dispos       Date:  1987 Mar-Apr       Impact factor: 3.922

9.  Enoxacin--a potent inhibitor of theophylline metabolism.

Authors:  J Beckmann; W Elsässer; U Gundert-Remy; R Hertrampf
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Decreased systemic clearance of caffeine due to cimetidine.

Authors:  L J Broughton; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

View more
  26 in total

1.  Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.

Authors:  F Sörgel; G Mahr; G R Granneman; U Stephan; P Nickel; P Muth
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 2.  [Central nervous system side effects of different antibacterial substances].

Authors:  G Stoppe; E Rüther
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Effects of moderate exercise on the pharmacokinetics of caffeine.

Authors:  K Collomp; F Anselme; M Audran; J P Gay; J L Chanal; C Prefaut
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.

Authors:  Ben D Snyder; Andrew Rowland; Thomas M Polasek; John O Miners; Matthew P Doogue
Journal:  Eur J Clin Pharmacol       Date:  2014-07-17       Impact factor: 2.953

Review 5.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 6.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 7.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

9.  Interaction between oral ciprofloxacin and caffeine in normal volunteers.

Authors:  D P Healy; R E Polk; L Kanawati; D T Rock; M L Mooney
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.